Expert-Driven Psychiatry Case: LAIs for Schizophrenia

Episode 1: Introduction and Case Report 1
Episode 2: Case Report 2
Episode 3: Case Report 3
Episode 4: Review the Data
Episode 5: Switch from Oral Treatment
Episode 6: Expected Results
Episode 7: Breakthrough Psychosis and Relapse
Episode 8: Case Report Summary

In this video, Christoph Correll, MD reviews three case reports for patients with schizophrenia who may be candidates to switch to long acting injectable (LAI) antipsychotics from oral medication. In this full-length video, he will:

• Introduce the three patients: 2 males, one female who range in age from 21-43
• Share data that highlights patient, clinician, and caregiver response to LAIs
• Share research that highlights the benefits of LAIs
• How to respond to breakthrough psychosis or continued relapse
• The role of LAIs with or without oral medication to avoid further psychosis

This deep dive into the clinically relevant and impactful role of LAIs will explain why Dr. Correll calls long acting injectables a “seatbelt on the road to recovery and success” for a breadth of patients living with schizophrenia.

Presented by The Journal of Clinical Psychiatry and Dramatic Health.

About the Faculty

Christoph U. Correll, MD is currently Professor of Psychiatry and Molecular Medicine at the Hofstra Northwell School of Medicine, New York, NY, USA and Medical Director of the Recognition and Prevention (RAP) programme at the Zucker Hillside Hospital, New York, USA. He is a board certified general psychiatrist and child and adolescent psychiatrist.

Professor Correll’s research and clinical work focuses on the identification, characterization and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.

Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 11 scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

Since 2014, the year of inception of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry.”